IMAGING TUMOR VARIATION IN RESPONSE TO PHOTODYNAMIC THERAPY IN PANCREATIC CANCER XENOGRAFT MODELS

被引:46
|
作者
Samkoe, Kimberley S. [1 ]
Chen, Alina [1 ]
Rizvi, Imran [1 ,2 ]
O'Hara, Julia A. [1 ]
Hoopes, P. Jack [1 ,3 ]
Pereira, Stephen P. [4 ]
Hasan, Tayyaba [2 ]
Pogue, Brian W. [1 ,2 ,3 ]
机构
[1] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03766 USA
[2] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Surg, Hanover, NH 03756 USA
[4] UCL, Sch Med, Inst Hepatol, London W1N 8AA, England
基金
美国国家卫生研究院;
关键词
Photodynamic therapy; Pancreatic cancer; Magnetic resonance imaging; Tumor aggressiveness; Orthotopic tumor; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; ADENOCARCINOMA; GEMCITABINE;
D O I
10.1016/j.ijrobp.2009.08.041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A treatment monitoring study investigated the differential effects of orthotopic pancreatic cancer models in response to interstitial photodynamic therapy (PDT), and the validity of using magnetic resonance imaging as a surrogate measure of response was assessed. Methods and Materials: Different orthotopic pancreatic cancer xenograft models (AsPC-1 and Panc-1) were used to represent the range of pathophysiology observed in human beings. Identical dose escalation studies (10, 20, and 40J/cm) using interstitial verteporfin PDT were performed, and magnetic resonance imaging with T2-weighted and T1-weighted contrast were used to monitor the total tumor volume and the vascular perfusion volume, respectively. Results: There was a significant amount of necrosis in the slower-growing Panc-1 tumor using high light dose, although complete necrosis was not observed. Lower doses were required for the same level of tumor kill in the faster-growing AsPC-1 cell line. Conclusions: The tumor growth rate and vascular pattern of the tumor affect the optimal PDT treatment regimen, with faster-growing tumors being relatively easier to treat. This highlights the fact that therapy in human beings shows a heterogeneous range of outcomes, and suggests a need for careful individualized treatment outcomes assessment in clinical work. (C) 2010 Elsevier Inc.
引用
收藏
页码:251 / 259
页数:9
相关论文
共 50 条
  • [41] Clinical impact of circulating tumor cells and therapy response in pancreatic cancer
    Okubo, K.
    Uenosono, Y.
    Arigami, T.
    Mataki, Y.
    Matsushita, D.
    Yanagita, S.
    Kurahara, H.
    Sakoda, M.
    Kijima, Y.
    Maemura, K.
    Natsugoe, S.
    EJSO, 2017, 43 (06): : 1050 - 1055
  • [42] In vivo fluorescence imaging to assess early therapeutic response to tumor progression in a xenograft cancer model
    Kim, Eun-Joong
    Lee, Hyunseung
    Yeom, Areum
    Hong, Kwan Soo
    BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 2016, 21 (04) : 567 - 572
  • [43] Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma
    Torphy, Robert J.
    Tignanelli, Christopher J.
    Kamande, Joyce W.
    Moffitt, Richard A.
    Loeza, Silvia G. Herrera
    Soper, Steven A.
    Yeh, Jen Jen
    PLOS ONE, 2014, 9 (02):
  • [44] In vivo fluorescence imaging to assess early therapeutic response to tumor progression in a xenograft cancer model
    Eun-Joong Kim
    Hyunseung Lee
    Areum Yeom
    Kwan Soo Hong
    Biotechnology and Bioprocess Engineering, 2016, 21 : 567 - 572
  • [45] Photodynamic therapy for palliation of unresectable pancreatic cancer.
    Rogowska, AZ
    Whitelaw, DE
    Lees, WR
    Gillams, AR
    Ripley, PM
    Buonaccorsi, GA
    Hatfield, AWR
    Bown, SG
    GUT, 1999, 44 : A48 - A48
  • [46] Perspectives on the Role of Photodynamic Therapy in the Treatment of Pancreatic Cancer
    Li, Wei
    Ma, Qingyong
    Wu, Erxi
    INTERNATIONAL JOURNAL OF PHOTOENERGY, 2012, 2012
  • [47] Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models
    Naoki Kamitani
    Ikuko Nakamae
    Noriko Yoneda-Kato
    Jun-ya Kato
    Masayuki Sho
    Scientific Reports, 12
  • [48] Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models
    Kamitani, Naoki
    Nakamae, Ikuko
    Yoneda-Kato, Noriko
    Kato, Jun-ya
    Sho, Masayuki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [49] Size-dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic Cancer Model
    Pigula, Michael
    Huang, Huang-Chiao
    Mallidi, Srivalleesha
    Anbil, Sriram
    Liu, Joyce
    Mai, Zhiming
    Hasan, Tayyaba
    PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2019, 95 (01) : 378 - 386
  • [50] CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy
    Jermyn, Michael
    Davis, Scott C.
    Dehghani, Hamid
    Huggett, Matthew T.
    Hasan, Tayyaba
    Pereira, Stephen P.
    Bown, Stephen G.
    Pogue, Brian W.
    PHYSICS IN MEDICINE AND BIOLOGY, 2014, 59 (08): : 1911 - 1921